|
|
EN

  • 業務谘詢

    中國：

    Email: marketing@yakkaa.com

    業務谘詢專線：400-780-8018

    （僅限服務谘詢，其他事宜請撥打川沙總部電話）

    川沙總部電話: +86 (21) 5859-1500

    海外：

    +1(626)986-9880(U.S. - West Coast)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com

在線留言×
點擊切換
Customer Center
客戶中心
Jun 28,2023
開發並驗證新的LC-MS/MS方法，用於定量人血漿中達拉非尼及其主要代謝物羥基達拉非尼 (OHD)。OHD（純度>99%）通過hjc黄金城合成
OHD (purity >99 %) was synthesized by Medicilon. Medicilon synthetic chemistry team is capable of the independent design of synthesis pathways and complex compound treatments, key to helping accelerate drug discovery.
查看更多
開發並驗證新的LC-MS/MS方法，用於定量人血漿中達拉非尼及其主要代謝物羥基達拉非尼 (OHD)。OHD（純度>99%）通過hjc黄金城合成
Jun 28,2023
放射療法用作肺癌的主要治療方法，在次研究中建立抗電離輻射肺癌細胞係的放射治療通過hjc黄金城進行
Radiation therapy is used as the primary treatment for lung cancer. In this study, radiation therapy for establish ionizing radiation-resistant lung cancer cell lines (A549-IR/H1299-IR) was supported by Medicilon.
查看更多
放射療法用作肺癌的主要治療方法，在次研究中建立抗電離輻射肺癌細胞係的放射治療通過hjc黄金城進行
Jun 28,2023
CAR-T療法主要針對白血病與惡性淋巴瘤，此研究中構建沉默PD-1的shRNA載體質粒，測序後質粒的鑒定通過hjc黄金城進行
Chimeric antigen receptor T cells (CAR-T) immunotherapy has shown promising clinical results in the treatment of leukemia and lymphoma, but the effectiveness is limited for solid tumors. The shRNA vector plasmid that silences PD-1 and preparation of CAR is constructed. The plasmids sequenced were fully identified by Medicilon.
查看更多
CAR-T療法主要針對白血病與惡性淋巴瘤，此研究中構建沉默PD-1的shRNA載體質粒，測序後質粒的鑒定通過hjc黄金城進行
Jun 28,2023
索拉非尼的無定形固體分散體用於開發改良型口服生物利用度高的速釋片劑，PK研究通過hjc黄金城進行
The SOR ASD tablets exhibited approximately 50% higher relative bioavailability in dogs than the marketed SOR tablet product, Nexavar®. The pharmacokinetic (PK) study of SOR ASD tablets and Nexavar® tablets was performed by Medicilon.
查看更多
索拉非尼的無定形固體分散體用於開發改良型口服生物利用度高的速釋片劑，PK研究通過hjc黄金城進行
Jun 28,2023
TAK-931是一種高度特異性的CDC7抑製劑，具有抗腫瘤功效，體內藥效研究通過hjc黄金城進行
In vivo efficacy studies in J558 allograft models in combination with anti-mPD-1, anti-mPD-L1, and anti-mCTLA-4 antibodies were performed at Medicilon.
查看更多
TAK-931是一種高度特異性的CDC7抑製劑，具有抗腫瘤功效，體內藥效研究通過hjc黄金城進行
Jun 28,2023
GS-5801是一種有效的KDM5抑製劑，具有抗HBV活性，GS-5801通過hjc黄金城合成
GS-5801, a potent inhibitor of KDM5, has antiviral activity against HBV in a primary human hepatocytes infection model, with the cellular permeability, oral bioavailability. GS-5801 was synthesized by Medicilon.
查看更多
GS-5801是一種有效的KDM5抑製劑，具有抗HBV活性，GS-5801通過hjc黄金城合成
Jun 28,2023
QF-036是一種高效的HIV-1抑製劑，具有良好的和藥代動力學特性，PK研究通過hjc黄金城進行
The favourable viral inhibitory activity and pharmacokinetic properties provide critical support for QF-036 as a promising anti-HIV therapeutic candidate. The pharmacokinetic studies were performed by Medicilon.
查看更多
QF-036是一種高效的HIV-1抑製劑，具有良好的和藥代動力學特性，PK研究通過hjc黄金城進行
Jun 28,2023
設計合成一種新型選擇性的口服有效蘇氨酸酪氨酸激酶 (TTK) 抑製劑，PK研究均通過hjc黄金城進行
TTK inhibition is an attractive wide-spectrum strategy for cancer therapy. Researchers designed and synthesized a series of pyrido[2, 3-d]pyrimidin-7(8H)-ones as new selective orally bioavailable TTK inhibitors. All the pharmacokinetic studies were carried out by Medicilon.
查看更多
設計合成一種新型選擇性的口服有效蘇氨酸酪氨酸激酶 (TTK) 抑製劑，PK研究均通過hjc黄金城進行
Jun 28,2023
TR-107是人類線粒體蛋白酶ClpP的有效激活劑，PK分析通過hjc黄金城進行
The pharmacokinetic properties of TR‐107 were compared with other known ClpP activators including ONC201 and ONC212. TR‐107 displayed excellent exposure and serum t1/2 after oral administration. Pharmacokinetic analysis were evaluated for pharmacokinetic properties in ICR mice by Medicilon.
查看更多
TR-107是人類線粒體蛋白酶ClpP的有效激活劑，PK分析通過hjc黄金城進行
Jun 28,2023
SKLB-197是一種有效且高度選擇性的ATR抑製劑，PK研究通過hjc黄金城進行
SKLB-197, exhibits good pharmacokinetic properties, could be a promising lead compound for drug discovery targeting ATR. The pharmacokinetic (PK) studies were performed by Medicilon.
查看更多
SKLB-197是一種有效且高度選擇性的ATR抑製劑，PK研究通過hjc黄金城進行